Nivolumab and pregnancy in patients with classical Hodgkin lymphoma
Open Access
- 17 July 2026
- journal article
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 227-237
Abstract
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.Keywords
This publication has 23 references indexed in Scilit:
- Publication OnlyHemaSphere, 2025
- Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsJAMA Network Open, 2024
- Severe Immune-Related Enteritis after In Utero Exposure to PembrolizumabNew England Journal of Medicine, 2023
- Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphomaAmerican Journal of Hematology, 2022
- Pregnancy outcome after early exposure to nivolumab, a PD-1 checkpoint inhibitor for relapsed Hodgkin’s lymphomaClinical Toxicology, 2021
- Single-cell profiling of the human decidual immune microenvironment in patients with recurrent pregnancy lossCell Discovery, 2021
- Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyJAMA Oncology, 2016
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009
- A critical role for the programmed death ligand 1 in fetomaternal toleranceJournal of Experimental Medicine, 2005
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998